We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-15.96%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$478M
AUM Growth
-$169M
Cap. Flow
+$26.7M
Cap. Flow %
5.59%
Top 10 Hldgs %
73.56%
Holding
41
New
2
Increased
3
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$21.7M
2
CTNM
Contineum Therapeutics
CTNM
+$9.48M
3
CRGX
CARGO Therapeutics
CRGX
+$5.59M
4
CYPH
Cypherpunk Technologies Inc
CYPH
+$4.65M
5
STRO icon
Sutro Biopharma
STRO
+$2.06M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$6.35M
2
ADVM
Adverum Biotechnologies
ADVM
+$4.12M
3
ZYME icon
Zymeworks
ZYME
+$4.08M
4
IMTX icon
Immatics
IMTX
+$2.23M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Financials 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRGX
1
DELISTED
CARGO Therapeutics
CRGX
$72.5M 15.17%
4,415,689
+294,000
+7% +$5.59M
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.35B
$59.4M 12.43%
5,074,916
– –
SRRK icon
3
Scholar Rock
SRRK
$5.71B
$56.5M 11.84%
6,788,609
– –
NGNE icon
4
Neurogene
NGNE
$696M
$46.1M 9.66%
1,267,790
– –
ACLX
5
DELISTED
Arcellx
ACLX
$25M 5.24%
453,641
– –
CLYM
6
Climb Bio
CLYM
$735M
$23.2M 4.85%
+3,261,393
New +$21.7M
NKTX icon
7
Nkarta
NKTX
$162M
$22.3M 4.66%
3,768,035
– –
LENZ
8
LENZ Therapeutics
LENZ
$172M
$20.9M 4.37%
1,208,473
– –
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$13.6M 2.85%
967,527
– –
JSPR icon
10
Jasper Therapeutics
JSPR
$22.9M
$11.9M 2.49%
525,000
– –
HLVX
11
DELISTED
HilleVax
HLVX
$11.6M 2.42%
799,274
– –
ABVX
12
Abivax
ABVX
$11B
$11.2M 2.35%
850,000
– –
SLRN
13
DELISTED
ACELYRIN
SLRN
$11.1M 2.33%
2,523,022
– –
CTNM
14
Contineum Therapeutics
CTNM
$526M
$10.4M 2.17%
+588,817
New +$9.48M
SYRS
15
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.22M 1.93%
1,786,427
– –
ZYME icon
16
Zymeworks
ZYME
$1.68B
$8.51M 1.78%
1,000,000
-458,875
-31% -$4.08M
RYTM icon
17
Rhythm Pharmaceuticals
RYTM
$7B
$7.09M 1.48%
172,647
– –
INZY
18
DELISTED
Inozyme Pharma
INZY
$6.97M 1.46%
1,562,500
– –
STRO icon
19
Sutro Biopharma
STRO
$379M
$6.44M 1.35%
219,681
+52,123
+31% +$2.06M
GOSS icon
20
Gossamer Bio
GOSS
$66.5M
$5.52M 1.16%
6,130,268
– –
TNGX icon
21
Tango Therapeutics
TNGX
$4.34B
$5.41M 1.13%
630,000
– –
VRNA
22
DELISTED
Verona Pharma
VRNA
$5.02M 1.05%
347,500
– –
CYPH
23
Cypherpunk Technologies Inc
CYPH
$66.2M
$4.79M 1%
2,442,352
+1,773,049
+265% +$4.65M
IOBT
24
DELISTED
IO Biotech
IOBT
$4.26M 0.89%
3,640,015
– –
VTVT icon
25
vTv Therapeutics
VTVT
$121M
$3.65M 0.76%
206,784
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q2 2024 Portfolio in Review

As of Q2 2024, Samsara BioCapital held 41 positions worth $478M, down 26% from $646M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Samsara BioCapital deployed $26.7M of net new capital in Q2 2024, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Climb Bio: 3,261,393 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $6.35M trimmed.

  • Samsara BioCapital's largest Q2 2024 buy was Climb Bio: 3,261,393 shares worth $23.2M.
  • Samsara BioCapital added most to CARGO Therapeutics in Q2 2024, an estimated $5.59M increase.
  • Samsara BioCapital's biggest Q2 2024 reduction was Janux Therapeutics, cutting an estimated $6.35M.
  • Samsara BioCapital fully exited Adverum Biotechnologies in Q2 2024, selling an estimated $4.12M.
  • Samsara BioCapital's ten largest holdings make up 74% of its $478M portfolio in Q2 2024.
  • Samsara BioCapital opened 2 new positions and closed 1 in Q2 2024.
  • Samsara BioCapital's portfolio value fell 26% quarter-over-quarter to $478M.

Based on Samsara BioCapital's 13F filing for Q2 2024, filed 14 Aug 2024.